Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated or antigen-mediated oe-sophageal disease. Therapeutic first-line options currently available for EoE are elimina-tion diets, proton pump inhibitors (PPIs) and steroids. The ultimate goal of the therapy is to avoid irreversible stricturing disease. Despite the rising prevalence of EoE, there has been little therapeutic advancement until recently. Dupilumab is one of the potential disease-modifying biologics used in various stages of clinical trials. The paper describes the case of a 10-year-old boy presenting with sub-oesophageal stricture in eosinophilic oesophagitis and steroid-dependence for disease control who was successfully treated with dupilumab.
Mainetti, M., Troisi, A., Turlà, G., Fontijn, S., Rametta, G., Buzzi, A., et al. (2022). Il dupilumab nell’esofagite eosinofila: una nuova frontiera?. MEDICO E BAMBINO, 41(1), 583-587 [10.53126/meb41583].
Il dupilumab nell’esofagite eosinofila: una nuova frontiera?
Marchetti, FedericoUltimo
Supervision
2022
Abstract
Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated or antigen-mediated oe-sophageal disease. Therapeutic first-line options currently available for EoE are elimina-tion diets, proton pump inhibitors (PPIs) and steroids. The ultimate goal of the therapy is to avoid irreversible stricturing disease. Despite the rising prevalence of EoE, there has been little therapeutic advancement until recently. Dupilumab is one of the potential disease-modifying biologics used in various stages of clinical trials. The paper describes the case of a 10-year-old boy presenting with sub-oesophageal stricture in eosinophilic oesophagitis and steroid-dependence for disease control who was successfully treated with dupilumab.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
